The combination with Amsterdam Molecular Therapeutics’s (AMT) adeno-associated virus (AAV) gene therapy platform potentially makes up a long-term treatment for this seriously debilitating disease with a single administration of the product.
Ronald Lorijn, CEO of AMT, said: “Access to La Sapienza’s RNA technology perfectly complements our gene and vector therapy platform. It adds a project to AMT’s R&D pipeline that will start its preclinical phase this year.”